The Recall Desk

State

New York product recalls

73,892 recalls have nationwide distribution and so reach New York. 12,964 additional recalls listed New York specifically in their distribution scope.

What the numbers show

Total
12,964
Critical
1,508
Severe
3,707
Most recent
2026-11-11

Of the 12,964 recalls naming New York we have scored against our rubric, 1,508 (12%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 3,707 (29%) are Severe.

These figures cover only the 12,964 recalls whose distribution notice names New York specifically. The 73,892 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

64551–64575 of 86856

  • SevereFDA (Drugs)·D-945-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trimeprazine Tartrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trimeprazine Tartrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trimeprazine Tartrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-636-2015·2015-04-29

    Attix Pharmaceuticals Recalls Docetaxel Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Docetaxel Anhydrous active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Docetaxel Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-719-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxocobalamin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-825-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ondansetron HCl Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ondansetron HCl Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ondansetron HCl Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-779-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mepivacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mepivacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mepivacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-804-2015·2015-04-29

    Mitotane API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Mitotane active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mitotane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-647-2015·2015-04-29

    Attix Pharmaceuticals Recalls EDTA Dipotassium Magnesium Salt Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-806-2015·2015-04-29

    Attix Pharmaceuticals Recalls Monobenzone Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Monobenzone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Monobenzone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Devices)·Z-1461-2015·2015-04-29

    Laax TigerPaw System II Implantable Occlusion Fastener Recalled for Tissue Tearing

    Laax, Inc. is recalling the TigerPaw System II implantable occlusion fastener due to field reports of possible tissue tearing and bleeding during use.

    Product
    TIGERPAW System II, Part number C-TP-1507 (7 connector) The TigerPaw System II is an implantable occlusion Fastener to be placed on the Ostium of the Left Atrial Appendage (LAA).
    Category
    Medical Device
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-634-2015·2015-04-29

    Attix Pharmaceuticals Recalls Disulfiram API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Disulfiram active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Disulfiram active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-862-2015·2015-04-29

    Primaquine Phosphate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Primaquine Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Primaquine Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-717-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Hydroxocobalamin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-620-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desmopressin Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desmopressin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Desmopressin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-533-2015·2015-04-29

    Attix Pharmaceuticals Recalls Azithromycin Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Azithromycin Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Azithromycin Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-560-2015·2015-04-29

    Carbazochrome API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Carbazochrome active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Carbazochrome active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-685-2015·2015-04-29

    Fluphenazine Decanoate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluphenazine Decanoate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Fluphenazine Decanoate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-710-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-499-2015·2015-04-29

    Acetazolamide API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Acetazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Acetazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-907-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfathiazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfathiazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Sulfathiazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-649-2015·2015-04-29

    Attix Pharmaceuticals Recalls Enzalutamide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling enzalutamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Enzalutamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-920-2015·2015-04-29

    Terbinafine Base Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Terbinafine Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Terbinafine Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-754-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levetiracetam Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levetiracetam active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levetiracetam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-918-2015·2015-04-29

    Attix Pharmaceuticals Recalls Temozolomide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Temozolomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Temozolomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-854-2015·2015-04-29

    Attix Pharmaceuticals Recalls Prazosin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Prazosin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Prazosin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-933-2015·2015-04-29

    Tobramycin Sulfate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tobramycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tobramycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide